GHGwo-Tzer Ho

Gwo-Tzer Ho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gwo-Tzer Ho has a total of 471 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reproducible ecological restructuring of the oral microbiome defines the oral-gut axis in Crohn’s disease

    by Rj. Whelan, Dif. Wands, P. Rimmer, R. Hansen, Dc. Wilson, G. Moran, J. Imai, Gl. Hold, Ilc. Chapple, T. Iqbal, et al.

    The oral microbiome is increasingly implicated in inflammatory bowel disease (IBD), yet findings across studies remain inconsistent and difficult to reconcile due to methodological heterogeneity. To resolve this, we performed a cross-cohort integration of oral microbiome datasets across 25 studies (n = 1,136 IBD; n = 759 controls), combined with unified re-analysis of publicly available sequencing data and newly generated in-house data within a single bioinformatic framework. Oral microbial diversity was consistently reduced in IBD (standardised mean difference –0.31, p = 0.007), with replication in the harmonised dataset (Hedges’ SMD = –0.372, p < 0.001), driven predominantly by Crohn’s disease (CD). Multivariable modelling identified a reproducible set of genera associated with disease, including enrichment of Corynebacterium , Serratia and Streptococcus . Network analysis demonstrated a fundamental ecological shift: whereas healthy communities were organised around a Selenomonas hub, CD exhibited integration of Corynebacterium into core network architecture, consistent with a shift toward an inflammation-adapted, aerotolerant ecological state. Functional predictions supported this restructuring, with depletion of butyrate metabolism and enrichment of aromatic amino acid degradation pathways. Together, these findings identify reproducible ecological restructuring of the oral microbiome in CD and establish a cross-cohort framework linking oral microbial organisation to the oral-gut axis in IBD. Abstract Figure:

  • Open Access

    Machine-learning approach to dissect the clinical heterogeneity of IBD-associated fatigue

    by Cher S Chuah, Rebecca Hall, Robert J Whelan, Peter D Cartlidge, Beatriz Gros, Eva Iglesias-Flores, Nikita Parkash, Ray K Boyapati, Clara Ramos-Belinchon, Solomon Ong, et al.

    Objective: Extreme and persistent fatigue affects >50% of individuals with inflammatory bowel disease (IBD), with similar prevalence across many common immune-mediated inflammatory diseases (IMIDs). Despite its ubiquity, human scientific studies have yet to fully explain the mechanistic basis of this complex symptom. One fundamental reason is our inability to account for the clinical heterogeneity and multifactorial nature of fatigue. Methods and analysis: We present the conceptual machine-learning (ML) framework to dissect fatigue using one of the largest prospectively captured, real-world patient-reported outcome (PROs) on well-being from three contemporaneous cohorts (2020–present), totalling 2970 responses from 2290 participants across the UK and internationally, including non-IBD controls with 100 lines of clinical metadata. In parallel, our patient public involvement group performed thematic analysis of this PRO dataset, which identified fatigue as a key research priority ( www.musicstudy.uk ). Results: We systematically defined the (1) threshold of fatigue as our primary outcome (≥10/14 fatigue days in 1604 patients (1151 responses in active disease and 1061 responses in remission; some patients measured longitudinally; median fatigue days 14 vs 7, respectively; p<0.001) to build our ML approach, (2) used routinely available clinical data that can be used at a population-level analysis, (3) employed seven different ML methods with external validation in three different cohorts in the UK, Spain and Australia (n=252), (4) employed Shapley Additive Explanations (SHAP) analysis to break down clinical heterogeneity and allow the examination of clinical predictive factors at an individual level; and finally, (5) investigated whether there are distinct clusters of fatigue patients. We found that ML models performed comparably (area under the curve/C-index ~0.7) on external validation with SHAP analysis showing interpretable, individualised fatigue drivers and five distinct fatigue cluster groups, including a subgroup with lower fatigue burden. Conclusions: Our data provide the ML ‘roadmap’ to predict and deconstruct fatigue in IBD and potentially more widely in IMIDs, enabling patient-level dissection beyond symptom-based classification with the ability to integrate deep molecular data. This is a step towards future clinical-scientific artificial intelligence models with immediate clinical application to stratify patients for human experimental studies to better identify patient-level patterns associated with fatigue. Trial registration number: NCT04760964 .

  • Open Access

    Patient-led thematic analysis on the impact of living with inflammatory bowel disease: a contemporary appraisal of 415 patient-reported outcomes to improve care and research

    by Molly J Halligan, Aerin E Thompson, Destiny Docherty, Patricia Kelly, Emma Pryde, Cher Shiong Chuah, Rebecca Hall, Gwo-Tzer Ho

    The conceptual context of wellbeing for people living with inflammatory bowel disease (IBD) is complex and encompasses many dimensions. Here, we employed a wholly patient-led analysis to provide a unique “patient first” narrative on wellbeing and IBD. Our report draws on data from a Wellbeing Survey led by the Glasgow and Edinburgh IBD Science team as part of the MUSIC IBD cohort study (www.musicstudy.uk) with over 1375 IBD respondents in 2023 from the United Kingdom and globally. Our public and patient involvement (PPI) group utilized unstructured patient-reported experiences and conducted a high-level topic analysis and based their own lived experience of IBD to explore and assimilate the 415 free-text responses on the priorities and unmet needs of our IBD participants. Within the PPI group, a transparent structure of patient-led analysis, identification of key topic areas, discussion, and finally writing was agreed at the start of the project with minimal input from the clinical team. The analysis provided an in-depth exploration of several key themes affecting wellbeing in IBD patients. Of interest, the PPI group discussed and explored themes such as “what does remission mean?,” access to care, expectations of self-management, mental and women’s health. The patient narratives highlighted the variability of IBD experiences, the interconnectedness of these issues, and the importance of holistic, patient-centric approaches to care. The findings emphasize the necessity for improved support, both within and beyond healthcare settings. The findings are written and presented by our PPI group to provide viewpoints that resonate directly with people living with IBD. Our patient-led research approach demonstrates that allowing patients to lead in analysis (“taking the reins”) and reporting provides deeper and impactful insights into IBD experiences. By shifting the lens of analysis via the patient when integrating their perspectives into wellbeing. This study thus, advocates for a patient-dominant approach to research and care, which can provide unique insights into ways to improve outcomes and to address the complexities of living with IBD.

  • Open Access

    Dynamic changes to the intestinal environment occur throughout recovery from experimental ischemic stroke

    by Rachel M L Martin, Isobel C Mouat, Robert J Whelan, Lizi M Hegarty, Lizzie F R Blunt, Christopher J Anderson, David H Dockrell, Calum C Bain, Gwo-Tzer Ho, Laura McCulloch

    Stroke survivors can experience a plethora of complications throughout their recovery that impair quality of life and impact neurological outcomes. Intestinal dysfunction is reported to occur rapidly following stroke in both humans and animal models and alterations such as reduced barrier integrity, lymphocyte loss and an altered microbiota have been suggested to contribute to increased brain injury. Despite the persistence of gastrointestinal symptoms in many stroke survivors, how the intestinal environment changes over the course of stroke recovery remains poorly understood. Here, we use an experimental model of ischaemic stroke to determine if gastrointestinal dysfunction persists into chronic recovery. We have shown that experimental stroke leads to structural alterations to the colon, a thinned mucus barrier, impaired transit times and an altered bacterial community composition. While barrier function and transit times recover within 2 weeks, structural and bacterial community alterations remain up to 3 months after stroke and are accompanied by altered luminal antibody profiles. Together, this suggests that the gastrointestinal system is dynamically altered over the course of experimental stroke recovery and highlight intestinal dysfunction as a target to improve patient outcomes beyond the acute recovery window.


  • A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel disease

    by Jamie I. Scott, Zhiming Cheng, Emily J. Thompson, Utsa Karmakar, Verity Cowell, Maya David, Doireann Gordon, Lorena Mendive-Tapia, Alexander Le Saint-Grant, Pia Volkmer, et al.

    The diagnosis and monitoring of inflammatory bowel disease (IBD) relies on histologic and endoscopic analysis, as well as measurements of generic markers of inflammation. However, there are no specific tests that report on T cell-mediated immune responses as a key driver of IBD pathogenesis. Here we detect increasing granzyme A (GzmA) in gut biopsies and confirm that CD8+ T cells secrete its active form to induce interleukin (IL)-8. We then rationally design a non-invasive chemiluminescence assay for measuring active GzmA in stool supernatants from patients with IBD. For our assay, we synthesize peptide-based GzmA-specific inhibitors and chemiluminescent reporters and use them to characterize biosamples from ~150 human patients with IBD and healthy controls. Our results demonstrate that GzmA activity is an indicator of gut inflammation that can enhance the identification of patients with IBD over existing tests and potentially act as a mechanistic biomarker for the dominance of T cell activity. We envision that the selectivity and sensitivity of our GzmA activity-based optical assay will accelerate the design of additional biomedical approaches to enhance precision medicine in IBD.


  • Open Access

    Heterogeneity of the intestinal mononuclear phagocyte compartment in health and inflammatory bowel disease

    by Thomas M. Fenton, Line Wulff, Venla Väänänen, Gareth-Rhys Jones, Camilla Koldbæk Lemvigh, Lene B. Riis, Mads Damsgaard Wewer, Julien Vandamme, Peter B. Jørgensen, Calum C. Bain, et al.

    Understanding of mononuclear phagocyte (MNP) diversity in the human intestine and the alterations this compartment undergoes in inflammation remains incomplete. Here, we used single-cell RNA sequencing, cellular indexing of trancriptomes and epitopes by sequencing, flow cytometry, and imaging to explore MNP heterogeneity in human ileal and colonic laminae propriae (LPs) in health and Crohn’s disease (CD). In addition to monocytes, macrophage subsets, and conventional type 1 dendritic cells (cDC1s) and cDC2s, we found a CD1c + cDC subset with transcriptional features of DC3s. Using computational tools, we identified monocyte-to-macrophage trajectories as well as putative subset–specific DC precursors. We further showed that LP CCR7 + cDCs are increased in CD and provided evidence that these cells arise from intestinal cDC2s/DC3s but not cDC1s. Collectively, these findings extend our current understanding of intestinal MNP diversity and development, highlighting both tissue-specific and inflammation-induced changes in MNP composition and function.


  • Open Access

    Tissue resident colonic macrophages persist through acute inflammation and adapt to aid tissue repair

    by Lizi M. Hegarty, Gareth-Rhys Jones, Claire E. Adams, Rebecca M. Gentek, Gwo-Tzer Ho, Elaine Emmerson, Calum C. Bain

    Macrophages are crucial for the maintenance of intestinal homeostasis, are considered key proinflammatory effector cells during intestinal inflammation and are implicated in tissue repair following injury or inflammation. Whether these roles are attributed to distinct subsets of macrophages or if macrophages retain a degree of plasticity in the intestine remains poorly understood. Here, through a combination of single cell RNA sequencing, lineage-tracing and immunofluorescence imaging, we define three major subpopulations of murine, colonic macrophages on the basis of CD11c and CD163 expression. These macrophages occupy discrete anatomical niches and display distinct replenishment kinetics. They all accumulate during acute colitis and Cx3cr1- based fate mapping shows that they persist through to inflammation resolution. Moreover, marked transcriptional differences exist between the macrophages present in health and their counterparts in the post-inflammation environment, demonstrating that inflammation leads to transcriptional rewiring of the resident macrophages in a subset-specific manner. Intriguingly, there were minimal transcriptional changes between long-lived macrophages and their recently differentiated counterparts, indicating the environment exerted a greater influence than ontogeny or the time of residency on their functional states in resolution.


  • Open Access

    Loss of HMGCS2-mediated intestinal stem cell ketogenesis is a metabolic barrier to mucosal healing in Ulcerative colitis

    by Duncan G Rutherford, Verity E Cowell, Robert J Whelan, Alexandra J B Cavanagh, Claire E Adams, Peter D Cartlidge, Phoebe Y Lau, Mairi H I Hodge, Nigel B Jamieson, Claire K Dietrich, et al.

    Human colonic epithelial cells express high levels of 3-Hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), the crucial mitochondrial enzyme responsible for the production ketone bodies, predominantly beta-hydroxybutyrate (βHB). Ketogenesis is an important metabolic pathway responsible for energy production in states of fasting and in the intestine ketone bodies are also important in regulating intestinal stem cell (ISC) homeostasis and regeneration. Using combined single-cell and spatial transcriptomics, organoids and prospective longitudinal mucosal analysis, we demonstrated a profound loss of ISC HMGCS2-mediated ketogenesis with consequential detrimental effect on Ulcerative colitis (UC), a chronic inflammatory bowel disease that affects ∼4 million individuals worldwide. We show that βHB restores UC ISC metabolic function, reduces cellular stress with further evidence of epigenetic programming key for restoration of ISC function. Furthermore, low colonic HMGCS2 expression is associated with treatment failure of multiple biological immune therapies in UC. Our findings reveal the crucial role for HMGCS2 and loss of ketogenesis as the ‘tipping point’ for pathogenic epithelial dysfunction and importantly, a promising metabolic therapeutic target for UC.


  • Open Access

    Machine learning approach to dissect the clinical heterogeneity of IBD-associated fatigue

    by Cher S Chuah, Rebecca Hall, Robert J Whelan, Peter D Cartlidge, Beatriz Gros, Eva Iglesias-Flores, Nikita Parkash, Ray K Boyapati, Clara Ramos-Belinchon, Solomon Ong, et al.

    Extreme fatigue is a clinical symptom that affects >50% of individuals with Inflammatory Bowel Disease (IBD), with a similar prevalence across many common immune-mediated inflammatory diseases (IMIDs). Despite its ubiquity, human scientific studies have yet to explain the mechanistic basis of this pervasive and complex symptom. One fundamental reason for this, is our inability to account for the clinical heterogeneity of fatigue with its multifactorial nature. We present the conceptual machine learning (ML) framework to dissect the complex nature of fatigue using one of the largest prospectively captured, real-world patient-reported outcome (PROs) on wellbeing from three contemporaneous cohorts (2020-present), totalling 2,970 responses from 2,290 participants across the UK and internationally, including non-IBD controls with 100 lines of clinical metadata. We systematically defined the (1) threshold of fatigue as our primary outcome (≥10/14 fatigue days) to build our ML approach, (2) utilised routinely available clinical data that can be used at a population-level analysis, (3) employed seven different ML methods with external validation in 3 different cohorts in UK, Spain and Australia (n=252), (4) employed Shapley Additive Explanations (SHAP) analysis to break down the clinical heterogeneity to allow the examination of clinical predictive factors at an individual level; and finally (5), investigate whether there are distinct clusters of fatigue patients. We found that ML models performed comparably (AUC/C-index ∼0.7) on external validation with SHAP analysis showing interpretable, individualised fatigue drivers and five distinct fatigue phenotypes, including a subgroup of young males with significantly lower fatigue burden. Our data therefore provides the ML ‘roadmap’ to predict and deconstruct fatigue in IBD and potentially also more widely in IMIDs, enabling patient-level dissection beyond symptom-based classification with the ability to integrate deep molecular data. This is a step towards future clinical-scientific AI models with the immediate clinical application to stratify patients to human experimental studies to better understand the dominant mechanisms that drive fatigue at an individual level.


  • Open Access

    DYNAMIC CHANGES TO THE INTESTINAL ENVIRONMENT OCCUR THROUGHOUT RECOVERY FROM EXPERIMENTAL ISCHAEMIC STROKE

    by Rachel M. L. Martin, Isobel C. Mouat, Robert Whelan, Lizi M. Hegarty, Christopher J. Anderson, David H. Dockrell, Calum C. Bain, Gwo-Tzer Ho, Laura McCulloch

    Stroke survivors experience a plethora of complications during recovery, including gastrointestinal symptoms. Intestinal dysfunction is reported to occur rapidly following stroke in both humans and animal models and alterations such as reduced barrier integrity, lymphocyte loss, and an altered microbiota have been suggested to contribute to poor neurological outcomes. Despite the persistence of gastrointestinal symptoms in many stroke survivors, how the intestinal environment changes over the course of stroke recovery remains poorly understood. Here, we use an experimental model of ischemic stroke to profile the gastrointestinal tract over a three month period of recovery.We have shown that experimental stroke leads to structural alterations to the colon, impaired transit times and an altered bacterial community composition. No impairments to barrier function were detected at any time point and transit times recover within 2 weeks post stroke. In contrast, structural and bacterial community alterations remain up to 3 months post stroke and are accompanied by abnormalities that develop only during chronic recovery, such as altered antibody coating of bacteria. These results suggest that the gastrointestinal system is dynamically altered over the course of experimental stroke recovery and that certain defects persist chronically after stroke.